HighTide Therapeutics (HKG:2511) and CEO Liu Liping as borrower agreed to terminate a HK$15 million loan agreement effective immediately.
No amount was drawn under the loan facility, according to a Thursday bourse filing.
The move came as the Hong Kong bourse raised concerns about non-compliance with the listing rules.
The stock exchange said the facility may not be on normal commercial terms or better and a partial exemption should not have been applied at the time of the loan grant.
The bourse said the deal should have been subject to a circular, independent financial advice, and shareholders' approval.